Floatz logo

Atv-1601

ER Positive Breast Cancer

Atavistik Bio, IncPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

76 Active assets in the ER Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Giredestrant
Hoffmann-La Roche
Phase 3BB

View all 50 →

Same molecule, other indications

Atv-1601 is also rated in:

cervical carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cervical cancerDormant
CC
Indicative ·
43 / 100
View asset →
uterine cervix neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →